Top in endocrinology: Research updates in obesity, diabetes treatments from ObesityWeek
Click Here to Manage Email Alerts
A pilot study revealed that patients treated with the antipsychotic olanzapine plus an intestinal microsomal triglyceride transfer protein inhibitor had an 82% reduction in postprandial triglycerides vs. those treated with olanzapine alone.
Additionally, the combined treatment resulted in lower weight gain vs. olanzapine alone.
A phase 2 proof-of-concept clinical study in patients who discontinued GLP-1 receptor agonists after weight loss for obesity is underway.
“Our primary endpoint is going to be the same mean change in postprandial triglyceride area under the curve, but we’ll also look at the effects of this GLP discontinuation alone and explore changes in body weight, fasting lipids and glycemic parameters,” William J. Sasiela, PhD, chief medical officer at Response Pharmaceuticals, said during a presentation at ObesityWeek.
It was the top story in endocrinology last week.
In another top story, results from the SURMOUNT-1 3-year trial showed that long-term tirzepatide reduced body weight and diabetes progression and was well tolerated in patients with obesity and prediabetes vs. placebo.
Read these and more top stories in endocrinology below:
New agent may help halt weight gain caused by antipsychotic drug
An intestinal microsomal triglyceride transfer protein inhibitor reduced postprandial triglycerides and halted weight gain in patients treated with the antipsychotic olanzapine, according to results of a pilot study presented at ObesityWeek. Read more.
GLP-1 alternative well-tolerated, could lead to similar rate of weight loss
Petrelintide, a novel once-weekly amylin analog, was well-tolerated in a cohort of healthy people with overweight or obesity, while conferring up to 8.6% weight loss at 16 weeks, a speaker reported at ObesityWeek. Read more.
Tirzepatide safe, effective for weight loss, preventing diabetes progression at 3 years
Tirzepatide demonstrated long-term weight-loss benefits and prevention of diabetes progression in patients with obesity and prediabetes, but the positive cardiometabolic effects reversed if they discontinued the weight-loss medication, a speaker reported at ObesityWeek. Read more.
GLP-1s reduce incident hypertension risk for adolescents with obesity
In adolescents with obesity, GLP-1 receptor agonists corresponded with lower risk for incident hypertension development 5 and 10 years after initiation vs. other anti-obesity medications, a speaker reported at ObesityWeek. Read more.
Weight loss medication access limited by care site, payer type, demographics
Access to GLP-1 medications is potentially impacted by care site, payer type and demographics, highlighting gaps in care that disproportionately affect certain patient subgroups, according to a presentation at ObesityWeek. Read more.